We bring our research, perspectives, industry expertise and relationships, along with our technology and data science capabilities, to deliver best-in-class longevity solutions, backed by peer-reviewed science. Our end-to-end service plugs into your practice and consists of:
Comprehensive vendor evaluation, recommendation, integrating logistics, data processing and operations. Our panels cover blood biomarkers, multi-omics, advanced imaging, wearables, and more.
Personalized, multi-dimensional health study (Patient 360), assessing where each patient is in their aging journey, and providing insights into potential determinants of their longevity.
Relevant longevity interventions that have been rated based on the strength of the peer-reviewed evidence. Our platform's intelligence capabilities identify and suggest personalized interventions to each patient's unique biology.
Orion, our Testing and Vendor Knowledge Base contains an up-to-date, PhD-curated library of peer-reviewed literature on longevity indicators, including aging biomarkers, system-level and disease risks, and relevant tests available for direct purchase or licensing. We provide a comprehensive analysis and detailed comparison of vendors for each test, based on the strength of the available evidence in the literature, as well as our own internal testing.
Data from vendors feeds into Polaris, our AI-driven Analysis and Reporting Engine. Polaris combines and interrogates the data to help us understand and quantify insights across multiple dimensions of health and wellness that are key to obtaining both a cross-sectional as well as a longitudinal view of a person's longevity prospects and risks. We use proprietary algorithms to synthesize these outputs and create a holistic view of the patient’s health.
Pegasus (aka Patient 360) is our Data Management and Research platform, purpose-built for longitudinal multi-modal data storage and analysis. It has capabilities to understand and process numerous types of raw test data, wearable data streams, insights and records. This includes the capability to analyze both cross-sectional and longitudinal that is made available to users, via our UI, APIs, or integration with business intelligence tools.
Frequently Asked Questions
Recently, there has been increased global interest in wellness, health, and longevity. However, for most consumers, longevity is being marketed through potentially dubious interventions, such as one-size-fits-all supplements, lotions, and technologies. These interventions are not rooted in peer-reviewed science, nor are they contextualized or personalized. While these can be good business for those selling, they rarely drive positive outcomes for patients. A better outcome would come from a focus on deep and forward-looking testing of each person’s detailed biology to assess the progression and effects of aging and risks of age-related or health-limiting diseases, followed by creation of personalized protocols.
Why a long-term focus on health and disease-prevention rather than treatment?
Age is the greatest risk factor for developing chronic disease. The global healthcare system allocates over 90% of its resources to disease care, while only a small fraction of the total budget is dedicated to wellness and disease prevention. We believe this should change and are working to promote an evidence-based, quantitative, data-informed approach to maintaining and improving health. Our products and services help catch disease early and identify actionable insights to maintain optimal health.
Our platform is ideally suited for clinics, practices and health professionals in functional medicine, integrative medicine, and concierge medicine, as well as government programs aimed at optimizing healthy longevity.
How is this different from current practices?
Because some of the technologies we use are newer and more costly, they have not yet been extensively integrated into clinical practice. However, all have been validated in a clinical setting. For example, our omics suite within Orion uses proteomics and metabolomics testing to look for signatures that are associated with metabolic and cardiovascular disease. While these technologies have not yet achieved mainstream adoption for diagnostic purposes, numerous studies indicate that they possess significant pre-diagnostic potential and can forecast the likelihood of disease onset and progression. Further, the volume of generated data is far too extensive for a human to process, compile, and comprehensively analyze to identify relevant patterns. Our proprietary algorithms are designed to optimally leverage this new abundance of information.
The Perennial Team
50 + years of collective experience in business, science and technology.
James Peyer, PhD
James is a Geroscientist and is the Chairman, providing strategic guidance and direction.
Prashant is the President and drives Business and Commercial functions and activities.
Elena Vayndorf, PhD
Elena is a Geroscientist and is the Chief Scientific Officer at Perennial, leading all science and research.
Bhushan is the Chief Technology Officer, and owns Product and Technology areas.
© 2024 Perennial Health Inc. All rights reserved